Swiss Insulin Pump Manufacturers (2026)

The Swiss insulin pump and drug delivery device landscape was redrawn in 2025. Ypsomed, the Burgdorf-based maker of the mylife YpsoPump, sold its diabetes care business to TecMed AG for up to CHF 420 million and refocused on GLP-1 autoinjectors and pens. Gerresheimer’s Sensile Medical in Olten holds the dominant Swiss micropump platform. SHL Medical in Zug runs the world’s largest autoinjector volume from outside Switzerland and is now adding Swiss production. This is the new map.

Switzerland’s Place in Global Drug Delivery

Switzerland is one of the world’s most concentrated drug delivery device clusters. According to the Swiss Medtech Sector Study 2024, the wider Swiss medtech sector generated CHF 23.4 billion in turnover in 2023 across approximately 1,400 companies, with 71,700 employees and a trade surplus of CHF 5.8 billion. 95% of those companies employ fewer than 250 people, and the sector reinvests over 12% of revenue into R&D, well above European averages.

Insulin pumps, patch pumps, pen injectors, autoinjectors, and micro-infusion devices sit at the high-value end of this map. They combine precision plastics, micro-electronics, drug-contact materials, and regulated combination-product engineering. Three names dominate the Swiss conversation: Ypsomed, Sensile Medical (Gerresheimer), and SHL Medical.

Ypsomed Burgdorf: The Pivot From Insulin Pumps to GLP-1

For two decades, Ypsomed in Burgdorf was synonymous with Swiss insulin pumps. The mylife YpsoPump plus mylife CamAPS FX algorithm and mylife Loop automated insulin dosing solution reached approximately 70,000 users by March 2025, and pump commercial sales grew 81% year on year in fiscal 2024/25, contributing CHF 175.3 million to the divested Diabetes Care segment’s CHF 236.9 million revenue, according to Ypsomed’s FY 2024/25 results announcement.

In April 2025, Ypsomed sold the entire Diabetes Care business to TecMed AG, a Burgdorf company controlled by Ypsomed founder Willy Michel, for up to CHF 420 million including earn-outs. Approximately 200 employees moved from the Solothurn facility to a new Burgdorf headquarters built for around 300 staff. The transaction closed in the second half of 2025.

Ypsomed CEO Simon Michel framed the rationale directly: “We are focusing on capturing substantial opportunities in the subcutaneous self-injection market and expanding our global production capacities.” Continuing Ypsomed is now a pure-play self-injection device manufacturer serving pharma and biotech, with CHF 502.3 million in Delivery Systems revenue in FY 2024/25, 30.4% segment growth, and autoinjector commercial sales up 50%.

The trigger is GLP-1. Ypsomed publicly disclosed a long-term manufacturing agreement with Novo Nordisk for large quantities of autoinjectors, with deliveries beginning in the 2025/26 fiscal year. In the first half of 2025/26, Delivery Systems sales reached CHF 266.6 million (up 21%) with autoinjector volumes growing 46.2%. Capacity expansions are running simultaneously in Schwerin (Germany), Changzhou (China), and a planned first U.S. plant in Holly Springs, North Carolina for 2027. Simon Michel told investors: “We operate in a market propelled by strong structural growth drivers, the shift to easy-to-use self-medication and the rise of biologics and biosimilars create vast growth opportunities.”

For procurement teams at pharma companies, the practical implication is straightforward. Ypsomed is now a self-injection CDMO, not an insulin pump brand. The pump brand and IP sit at TecMed.

TecMed AG Burgdorf: The New Swiss Insulin Pump Pure-Play

TecMed AG is the new home of Swiss insulin pump manufacturing. It combines Ypsomed’s tube-pump system (mylife YpsoPump, mylife Loop, mylife CamAPS FX) with the patch-pump development program also acquired from Ypsomed. The combined entity is positioned as a focused diabetes infusion systems manufacturer with both tube and patch pump platforms under one roof and approximately 300 staff at the new Burgdorf headquarters. It is the only sizeable insulin pump company headquartered in Switzerland.

For Swiss precision manufacturers, this matters for two reasons. First, TecMed inherits the Ypsomed supply chain for plastics, electronics, and sub-assemblies and will need to consolidate and rationalize it. Second, a structured pump roadmap is in motion, including patch pumps that compete with Insulet’s Omnipod, Tandem’s Mobi, and Medtronic’s MiniMed 780G in markets where the YpsoPump and CamAPS FX brand is already established.

Sensile Medical (Olten): The Gerresheimer Micropump Platform

In Olten, Sensile Medical is the Swiss center of micro-infusion device development for German packaging and drug delivery giant Gerresheimer, which acquired Sensile in 2018. The core IP is the SenseCore micro rotary piston pump, a two-plastic-part precision dosing engine that enables programmable subcutaneous delivery profiles for on-body patch pumps and connected infusion devices.

Sensile is not a finished insulin pump brand. It is an OEM platform for pharma companies that want to launch their own branded patch pump combined with a specific drug. The Sanofi-Verily insulin patch pump program for type 2 diabetes and the EVER Pharma micro-infusion pump for Parkinson’s disease both run on this platform. As GLP-1 therapies move toward higher dosing volumes, weekly schedules, and on-body wear-time profiles, the Sensile/Gerresheimer combination is positioned for high-viscosity biologic patch delivery that traditional pen injectors cannot handle.

SHL Medical (Zug): The Autoinjector Volume Leader Returns to Switzerland

SHL Medical, headquartered in Zug, is the world’s largest independent autoinjector manufacturer and the maker of the device behind multiple blockbuster biologics. The company is on track to deliver 1.5 billion devices in 2025, according to its Charleston facility opening announcement. Production has historically been concentrated in Taiwan, but the map is shifting.

In March 2025, SHL inaugurated a US$220 million, 360,000-square-foot fully automated injection molding and assembly plant in North Charleston, South Carolina. CEO Ulrich Faessler described the move as “a major step forward in our global expansion.” Adjacent to that, SHL has committed to a new manufacturing site in Zug’s Tech Cluster with construction expected to complete in 2026. Once Zug is online, SHL becomes the only autoinjector manufacturer producing across three continents: Asia (Taiwan), North America (South Carolina), and Europe (Switzerland and Germany).

While SHL is adjacent to insulin pumps rather than a direct pump manufacturer, GLP-1 demand makes it impossible to ignore in any serious map of Swiss drug delivery manufacturing. Most GLP-1 pens and autoinjectors reaching pharmacies globally are produced or designed by Ypsomed, SHL, or Gerresheimer.

Why GLP-1 Demand Reshapes the Sector

GLP-1 receptor agonists have created the most severe injection device supply squeeze in modern pharma history. Every major device manufacturer is racing to add billions of units of annual capacity. Swiss manufacturers are at the center because they own the precision injection-molding, electronic dosing, and combination-product regulatory know-how that GLP-1 sponsors need. Ypsomed is building in Schwerin, Changzhou, and Holly Springs. SHL is building in Charleston and Zug. Gerresheimer is scaling Sensile’s micropump platforms. Sales scale is no longer the binding constraint, manufacturing capacity is.

Conventional Sales Channels Are Under Pressure

Swiss insulin pump and drug delivery manufacturers have historically depended on a small number of well-worn channels to win pharma, distributor, and hospital business. Each one is showing real limits in the post-2024 environment.

Diabetes Distribution Networks and Hospital Tenders: Slow and Locked

Insulin pump distribution in Europe runs through national diabetes distributors and hospital tender systems. Hospital pharmacies still hold roughly 54% of diabetes device distribution share globally, but building distributor coverage in a new country takes 12 to 24 months of regulatory registration, clinical training, and reimbursement negotiation. Group purchasing organizations buy on framework agreements that lock pricing for 2 to 4 years and require MDR documentation, post-market surveillance data, and clinical evidence to win. Valuable but slow.

Pharma Sales Reps Calling on Endocrinologists: Saturated

The traditional channel for pumps, pens, and CGMs is field sales reps calling on endocrinologists and diabetes nurse educators. A specialised diabetes device sales rep in the EU or US runs $120,000 to $200,000 fully loaded with cost per qualified lead in the $500 to $1,200+ range. Endocrinologists already see Medtronic, Insulet, Tandem, Roche, Abbott, Dexcom, and now Eli Lilly and Novo Nordisk weekly. The channel is saturated for incumbents and prohibitively expensive for a smaller manufacturer expanding into new geographies.

Trade Fairs: Useful but Linear

ADA Scientific Sessions, EASD in Europe, ATTD, MEDICA in Dusseldorf, COMPAMED for components, and Pharmapack Europe for drug delivery are the standing list. A mid-size Swiss device or component manufacturer attending three to four of these per year burns CHF 80,000 to 150,000 with cost per qualified lead in the $300 to $900+ band. Fairs scale linearly: double the booths, double the cost.

Cold Calling and Distributor Lock-In

Cold outreach into pharma BD and combination-product teams works when done in the buyer’s native language with full command of dosing volumes, viscosity, primary container compatibility, and regulatory class. Building that capability in-house across English, German, French, Japanese, and Mandarin is out of reach for most Swiss SMEs. And insulin pump companies that sell through diabetes distributors give up 15 to 30% of revenue and visibility into the end customer. When you need to pivot indications or geographies, the distributor relationship does not pivot with you.

How AI-Powered Outbound Fits the New Swiss Drug Delivery Map

An AI-powered outbound engine is built for the specific shape of this market: a small number of very high-value pharma sponsors, a global geography, multiple regulatory languages, and procurement cycles measured in quarters rather than weeks.

Pharma Sponsor Mapping at Scale

The buyers a Swiss insulin pump or drug delivery manufacturer needs to reach are pharma BD, drug delivery innovation, and combination-product procurement teams at companies with biologics, peptides, or GLP-1 programs in clinical or commercial stage. AI outbound builds and maintains that target map across Novo Nordisk, Eli Lilly, Sanofi, Roche, Pfizer, AstraZeneca, Boehringer Ingelheim, and 200+ smaller specialty pharma companies, then runs research-grade personalized outreach in each contact’s native language.

Signal-Based Targeting for Combination Products

The system monitors signals that matter for drug delivery: new clinical trial registrations for subcutaneous biologics, FDA combination-product designations, primary container switching announcements, partnership press releases, executive moves into drug delivery roles, and capacity build announcements. When a sponsor signals an active device sourcing decision, the message arrives at the moment of relevance, not three months later.

Regulatory and Engineering Fluency

Each message references ISO 13485, ISO 11608 for pen injectors and autoinjectors, MDR Class IIb classification for insulin pumps, FDA 510(k) and combination-product pathways, primary container fit, viscosity ranges, and human factors data. This is the language pharma sourcing teams expect. Generic outbound never reaches them.

Year-Round Pipeline Instead of Conference-Driven Selling

Instead of concentrating BD effort around Pharmapack in February and ATTD in March, the engine creates a continuous pipeline of conversations with sponsors globally. ADA and Pharmapack become moments to deepen relationships that began months earlier.

Compounding Cost Curve

Trade fairs and field reps scale linearly or worse. AI outbound gets cheaper over time: the second 1,000 prospects cost less than the first 1,000, because targeting, messaging, and timing improve with every cycle. Cost per qualified pharma lead starts at $150 to $300 and decreases as the engine learns.

What the First 90 Days Look Like

Days 1 to 30: Foundation. Define the device platforms, dosing volumes, viscosity range, regulatory clearances, capacity available for new programs, and target therapeutic areas. Build the pharma sponsor target list and configure messaging that leads with platform fit and Swiss manufacturing credibility.

Days 31 to 60: Launch and Learn. Begin outreach across English, German, French, and Japanese. Track which therapeutic areas and company sizes respond. Real conversations with pharma BD and drug delivery teams typically begin in this window.

Days 61 to 90: Scale and Optimize. Expand to additional geographies and combination-product opportunities. Layer in clinical trial and capacity-signal monitoring. By day 90, expect multiple active pharma evaluations in motion.

Frequently Asked Questions

Who are the main Swiss insulin pump manufacturers in 2026?

After Ypsomed’s April 2025 sale of its diabetes care business, TecMed AG in Burgdorf is now the dominant Swiss-headquartered insulin pump company, holding the mylife YpsoPump, mylife Loop, mylife CamAPS FX, and a patch pump development program. Sensile Medical in Olten, owned by Gerresheimer, is the leading Swiss micropump OEM platform for partner-branded patch pumps. Ypsomed itself has pivoted to autoinjectors and pens for GLP-1 and other biologics, and SHL Medical in Zug is building Swiss autoinjector production.

Did Ypsomed exit insulin pumps entirely?

Yes. Ypsomed sold its full diabetes care business to TecMed AG for up to CHF 420 million in April 2025, including the mylife YpsoPump, the patch pump development program, and approximately 200 staff. The continuing Ypsomed business is a pure-play self-injection device CDMO focused on autoinjectors and pens for pharma and biotech partners.

How is GLP-1 demand reshaping Swiss drug delivery manufacturers?

GLP-1 receptor agonists for diabetes and weight management have created an unprecedented autoinjector and pen capacity shortage. Ypsomed signed a major supply agreement with Novo Nordisk and is expanding in Schwerin, Changzhou, and Holly Springs. SHL Medical opened a US$220 million Charleston plant and is building Swiss capacity in Zug. Gerresheimer’s Sensile platform targets higher-volume biologic patch pumps. Capacity, not demand, is the binding constraint.

What buyers should Swiss drug delivery manufacturers be targeting?

The highest-value buyers are pharma and biotech business development, drug delivery innovation, and combination-product procurement teams at companies with subcutaneous biologic, peptide, or GLP-1 programs. Hospital procurement and diabetes distributors remain relevant for branded insulin pump and patch pump sales, but the strategic growth comes from pharma sponsor relationships for OEM and combination-product device supply.

Is AI outbound appropriate for regulated combination-product sales cycles?

Yes, when configured for the regulatory and engineering depth of the buyer. Combination-product procurement cycles run 6 to 24 months from first contact to program decision. AI outbound accelerates the top of the funnel by getting your device platform into the consideration set during the earliest sourcing conversations. Real evaluations begin in 60 to 90 days, and first qualified programs typically take 6 to 12 months.

The Bottom Line

The Swiss insulin pump and drug delivery map looks nothing like it did in early 2024. Ypsomed is now a GLP-1 and biologics self-injection CDMO. TecMed AG owns the Swiss insulin pump brand portfolio. Sensile Medical under Gerresheimer is the micropump platform for next-generation patch pumps. SHL Medical is bringing autoinjector volume back to Swiss soil.

The traditional channels of distributors, hospital tenders, endocrinology field sales, and trade fairs cannot keep up with the speed of this reshuffling. The Swiss manufacturers that build direct pipelines into pharma sponsors, drug delivery scouts, and combination-product procurement teams now will be the ones that capture the next wave of GLP-1 and biologic programs. The ones that wait for the next Pharmapack will keep competing for booth traffic.

If you are a Swiss insulin pump, patch pump, autoinjector, or drug delivery component manufacturer ready to reach pharma sponsors directly, start a conversation with us. We will show you exactly how AI-powered outbound works for your platform. Also read our Swiss medtech sector view, the Swiss pharma and biotech exporters guide, the Switzerland manufacturing exports overview, or browse our case studies.